STORY SUMMARY

FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery

The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact…

This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.

Read original reporting ↗

More from FDA Press Releases · Latest headlines